Clinical Trials Logo

Clinical Trial Summary

Cancer is one of the main causes of death globally, being in many countries the first cause of mortality. One of the main side effects of chemotherapy and/or radiotherapy treatment in cancer patients is the alteration of taste and smell, internationally known as these anomalies Taste Smell Alterations (TSA). These alterations are the result of an altered cellular structure, the presence of TSA is associated with reduced quality of life and poor nutrition, due to dietary changes made by these patients. Synsepalum dulcidicum (dried miracle berry, DMB) is a plant belonging to the Sapotaceae family, made up of around 800 species grouped into around 40 genera. It is an indigenous species to the forest regions of West Africa. Nuts of this specie have been approved as a novel food in accordance with Regulation (EU) 2015/2238 and at the request of the European Commission through the European Food Safety Authority (EFSA) Panel on Nutrition, Novel Foods and Food Allergens. The characteristic component of DMB is miraculin. Miraculin is a glycoprotein whose consumption causes acidic and sour foods, and to a lesser extent bitter, to be perceived as having a sweet taste. In this sense, it is possible that the consumption of DMB before each meal can improve sensory perception after treatment with chemotherapy or radiotherapy.


Clinical Trial Description

Randomized, parallel, triple-blind, controlled clinical trial to evaluate the effect of habitual consumption of DMB on the olfactory-gustative perception in cancer patients with moderate malnutrition. 30 volunteers will be recruited at the La Paz University Hospital of Madrid. Participants should meet the next inclusion criteria: men and women over 18, a weight loss of 5 to 10%, moderate malnutrition, taste alterations, cancer patients treated with neoadjuvant chemotherapy prior to surgery, chemotherapy or chemo-radiotherapy who are not candidates for surgery, with less than or equal to one third of chemotherapy and/or radiotherapy treatment initially scheduled, a life expectancy greater than 3 months, oral intake of food and drinks, adequate cultural level and understanding of the clinical study. Participants will be randomized in 3 arms: 1. Group A (150mg de DMB equivalent to 2, 8 mg of miraculin glycoprotein + 150g of freeze-dried strawberry). 2. Group B (300 mg of DMB equivalent to 5, 5 mg of the miraculin glycoprotein). 3. Group C (300 mg of strawberry lyophilisate). Follow up will include 6 individualized visits, to perform the following tests at each visits: Selection visit • Nutritional assessment • Electrogustometry • Olfactory-gustative test (test strips) - Taste and smell survey. 1º visit: - Measurement of blood pressure and heart rate - Morphofunctional assessment: o Anthropometry measures (weight, % weight loss, height, BMI, ICA) o Bioelectrical impedance (BIA): musculoskeletal mass index (MMI), phase angle (FA), extracellular water (EW), intracellular water (IW) and total water (TBW), fat mass (FM), muscle mass (MM), total cell mass, representation phase angle vector (BIVA) o Dynamometry o Nutritional ultrasound o Functionality test (Up and Go Test) - Olfactory-gustative test (Sniffin'Stick Smell Test) - Saliva volume. - Analytic: o Biochemistry (albumin, prealbumin, retinol-binding protein (RBP), glucose, lipid profile (Total Cholesterol (TC), triglycerides (TG), HDL, LDL), safety parameters (transaminases, urate, creatinine), fat-soluble vitamins (A, D, E), B12, folate, iron metabolism, Zn, Se. Hemogram, lymphocytes, coagulation, hsCRP) o Stool microbiota and metagenome o Saliva microbiota and metagenome o Plasma metabolomes o Quantitative profile of fatty acids in erythrocytes (enzymatic activity of catalase (CAT), superoxide dismutase (SOD), glutathione-reductase (GR) and glutathione peroxidase (GPOX)) o Plasma cytokine profile (Interleukin (IL) 1β, 4, 6, 8, 10 tumor necrosis factor (TNFα), interferon γ (IFNγ), sIL6R, sTNFR) o Metabolites in urine o System status of antioxidant status (hydroxyguanosine and F2-Isoprostanes) 2º visit: - Anthropometric measures - Electrogustometry - Olfactory-gustative test - Saliva volume - Taste and smell survey - Product efficacy satisfaction questionnaire (post-QTx) 3º and 4º visit: - Morphofunctional assessment: - Measurement of blood pressure and heart rate, - Electrogustometry - Olfactory-gustative test - Saliva volume - Taste and smell survey - Product efficacy satisfaction questionnaire (pre-QTx) - Analytic: o Biochemistry o Stool microbiota and metagenome (v3) o Saliva microbiota and metagenome o Plasma metabolomes o Quantitative profile of fatty acids in erythrocytes o Plasma cytokine profile o Metabolites in urine o System status of antioxidant status 5º visit: - Morphofunctional assessment: - Measurement of blood pressure and heart rate, - Electrogustometry - Olfactory-gustative test - Saliva volume - Taste and smell survey - Product efficacy satisfaction questionnaire (pre-QTx) - Analytic: o Biochemistry o Stool microbiota and metagenome (v3) - Saliva microbiota and metagenome - Plasma metabolomes - Quantitative profile of fatty acids in erythrocytes - Plasma cytokine profile - Metabolites in urine - System status of antioxidant status ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05486260
Study type Interventional
Source Instituto de Investigación Hospital Universitario La Paz
Contact Bricia López-Plaza, PhD
Phone +34 917277000
Email [email protected]
Status Recruiting
Phase N/A
Start date June 23, 2022
Completion date June 30, 2023

See also
  Status Clinical Trial Phase
Recruiting NCT05094804 - A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With a PD-1 Inhibitor Phase 1/Phase 2
Active, not recruiting NCT04867850 - Effect of Behavioral Nudges on Serious Illness Conversation Documentation N/A
Enrolling by invitation NCT04086251 - Remote Electronic Patient Monitoring in Oncology Patients N/A
Completed NCT01285037 - A Study of LY2801653 in Advanced Cancer Phase 1
Completed NCT00680992 - Study of Denosumab in Subjects With Giant Cell Tumor of Bone Phase 2
Completed NCT00062842 - Study of Irinotecan on a Weekly Schedule in Children Phase 1
Recruiting NCT04548063 - Consent Forms in Cancer Research: Examining the Effect of Length on Readability N/A
Completed NCT04337203 - Shared Healthcare Actions and Reflections Electronic Systems in Survivorship N/A
Recruiting NCT04349293 - Ex-vivo Evaluation of the Reactivity of the Immune Infiltrate of Cancers to Treatments With Monoclonal Antibodies Targeting the Immunomodulatory Pathways N/A
Terminated NCT02866851 - Feasibility Study of Monitoring by Web-application on Cytopenia Related to Chemotherapy N/A
Active, not recruiting NCT05304988 - Development and Validation of the EFT for Adolescents With Cancer
Completed NCT00340522 - Childhood Cancer and Plexiform Neurofibroma Tissue Microarray for Molecular Target Screening and Clinical Drug Development
Recruiting NCT04843891 - Evaluation of PET Probe [64]Cu-Macrin in Cardiovascular Disease, Cancer and Sarcoidosis. Phase 1
Enrolling by invitation NCT03844048 - An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial Phase 3
Active, not recruiting NCT03109041 - Initial Feasibility Study to Treat Resectable Pancreatic Cancer With a Planar LDR Source Phase 1
Completed NCT03167372 - Pilot Comparison of N-of-1 Trials of Light Therapy N/A
Terminated NCT01441115 - ECI301 and Radiation for Advanced or Metastatic Cancer Phase 1
Recruiting NCT04444544 - Quality of Life and High-Risk Abdominal Cancer Surgery
Completed NCT04281953 - Impact on Quality of Life of Long-term Ototoxicity in Cancer Survivors
Recruiting NCT02478931 - Study of Personalized Cancer Therapy to Determine Response and Toxicity